logo-loader

PROLOR receives positive results from comparative study of hemophilia drug

Published: 17:52 15 Sep 2011 BST

no_picture_pai

PROLOR Biotech (AMEX:PBTH) announced Thursday it received positive preclinical results from a comparative study of its Factor VIIa-CTP drug, intended for the long-lasting treatment of hemophilia.

Hemophilia is hereditary genetic disorder that reduces levels of the Factor VIII or Factor IX proteins, impairing the body's ability to control blood clotting or coagulation. Patients with severe forms of the disease can be severely affected by even the most minor injury, resulting in debilitating blood loss that continues for days or weeks, permanent damage to joints and organs, and, in some cases, death.

PROLOR's Factor VIIa is already commercially available. This new version utilizes the company's CTP technology, which lengthens the drug's half-life, or the amount of time for the substance to be consumed by half in the decaying process.

The study compared the efficacy of the CTP-enable drug with its original counterpart in hemophilic mice. Subjects who received the Factor VIIa-CTP drug displayed a longer duration of clotting activity.
President Shai Novik commented: "We believe the results of our first Factor VIIa-CTP preclinical study are very promising and they are consistent with the results we obtained from a preclinical study of our other blood coagulant agent in development, clotting Factor IX-CTP.

"With the positive results from this Factor VIIa-CTP study, we now have what we believe are two highly competitive coagulation therapies in development that address a target market estimated at approximately $2 billion."
CEO Dr. Abraham Havron added: "We believe there is great need among hemophilia patients and their physicians for new therapies that will provide prolonged protection from bleeding.

"The encouraging results seen in our preclinical hemophilia study show that Factor VIIa-CTP may be able to offer an improved therapeutic option to the many hemophilia patients who are not well protected by current therapies."

PROLOR's shares jumped 2.38% as of 11:57 am EDT, to $4.30.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

52 minutes ago